Related Experiment Video
Updated: Feb 13, 2026

Live Imaging of Drug Responses in the Tumor Microenvironment in Mouse Models of Breast Cancer
Published on: March 24, 2013
Identification of Potential Therapeutic Targets Among CXC Chemokines in Breast Tumor Microenvironment Using
Erbao Chen1, Xuan Qin2, Ke Peng1
1Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Background/Aims:
Breast cancer is a common cause of cancer mortality throughout the world. The cross-talk between cancer cells and interstitial cells exerts significant effects on neoplasia and tumor development and is modulated in part by chemokines. CXC is one of four chemokine families involved in mediating survival, angiogenesis, and immunosensitization by chemoattracting leukocytes, and it incentivizes tumor cell growth, invasion and metastasis in the tumor microenvironment. However, the differential expression profiles and prognostic values of these chemokines remains to be elucidated.
Methods:
In this study, we compared transcriptional CXC chemokines and survival data of patients with breast carcinoma (BC) using the ONCOMINE dataset, Kaplan-Meier Plotter, TCGA and cBioPortal.
Results:
We discovered increased mRNA levels for CXCL8/10/11/16/17, whereas mRNA expression of CXCL1/2/3/4/5/6/7/12/14 was lower in BC patients compared to non-tumor tissues. Kaplan-Meier plots revealed that high mRNA levels of CXCL1/2/3/4/5/6/7/12/14 correlate with relapse-free survival (RFS) in all types of BC patients. Conversely, high CXCL8/10/11 predicted worse RFS in BC patients. Significantly, high transcription levels of CXCL9/12/13/14 conferred an overall survival (OS) advantage in BC patients, while high levels of CXCL8 demonstrated shorter OS in all BC sufferers.
Conclusions:
Integrative bioinformatics analysis suggests that CXCL8/12/14 are potential suitable targets for precision therapy in BC patients compared to other CXC chemokines.
More Related Videos
07:13Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
Published on: March 26, 2014
06:56A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
Published on: March 10, 2018
Related Concept Videos
The Tumor Microenvironment
Pharmacogenomics: Identification of New Drug Targets
Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Index
Integration by Parts: Indefinite Integrals
Integration by Parts: Definite Integrals